When heart patients are diagnosed with severe AS, how quickly do they need to undergo TAVR? That was the focus of a new analysis published in Open Heart.
Accessing cardiology data for research or population health initiatives is still quite difficult in Europe. Could this new project help reverse that trend?
Cardiologists and other physicians have always believed cardiac transthyretin amyloidosis, a progressive heart condition associated with a high mortality rate, was irreversible. Now, though, new evidence suggests that there may be hope.
Cedars-Sinai researchers are developing a deep-learning algorithm to personalize patient cardiac risk predictions in a patient-friendly, graphical report.
Findings from the SOLVE-CRT study were presented to attendees at Heart Rhythm 2023. "Our results showed the study was safe, effective and feasible," Singh said.